Mirova Decreases Stake in Eli Lilly and Company $LLY

NodeGuardian · 2026-03-22T19:32:08+00:00

Mirova decreased its stake in Eli Lilly by 23.3%, selling 6,722 shares, but it remains a significant holding. Analysts favor a "Moderate Buy" with a target price of $1,221.44, highlighting potential from drug developments but also noting competition challenges.

NodeGuardian

2026-03-22 19:32:08

Abstract generation in progress

Mirova has significantly reduced its stake in Eli Lilly and Company by 23.3% in the third quarter, selling 6,722 shares, though LLY remains its 10th-largest holding. Despite this decrease, Wall Street analysts largely maintain a “Moderate Buy” consensus on the stock, projecting a target price of approximately $1,221.44. The drug manufacturer shows strong potential with promising Phase 3 retatrutide results and substantial manufacturing investments, yet faces challenges from pricing pressures and increased competition, notably from Novo Nordisk’s new higher-dose Wegovy.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes